Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Sdgla who wrote (1267658)	10/8/2020 9:54:22 PM
From: Bonefish	4 Recommendations Recommended By locogringo Mick Mørmøny Sdgla Winfastorlose Read Replies (1) \| Respond to of 1577915

Trump voters are silent. But will get out and vote because the stakes are high. Vote Trump or lose your country.

To: Sdgla who wrote (1267658)	10/8/2020 10:01:38 PM
From: sylvester80	2 Recommendations Recommended By J_F_Shepard rdkflorida2 Respond to of 1577915

BOMBSHELL: The treatment that Trump touted as a ‘cure’ for Covid-19 was developed using cells derived from fetal tissue... a practice that tRump's own administration has moved to restrict The antibody cocktail for Covid-19 that President Trump touted on Wednesday afternoon was developed with cells originally derived from fetal tissue, a practice that his administration has moved to restrict. In June 2019, the Trump administration suspended federal funding for most new scientific research involving fetal tissue derived from abortions. “Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trump’s administration,” the Department of Health and Human Services said in a statement in 2019, around the time of the ban. “Intramural research that requires new acquisition of fetal tissue from elective abortions will not be conducted,” the statement added. Mr. Trump last week received Regeneron’s cocktail of monoclonal antibodies — essentially, antibodies synthesized in living cells and administered to help the body fight off the infection. To develop the antibodies, Regeneron relied on 293T, a cell line derived from the kidney tissue of an aborted fetus in the 1970s. At least two companies racing to produce vaccines against the coronavirus, Moderna and AstraZeneca, also are using the cell line. Remdesivir, an antiviral drug Mr. Trump received, also was tested using these cells. “293Ts were used in testing the antibodies’ ability to neutralize the virus,” said Alexandra Bowie, a spokeswoman for Regeneron. “They weren’t used in any other way, and fetal tissue was not used in the research.” In a video released Wednesday, Mr. Trump praised Regeneron’s treatment, calling it a “cure” for Covid-19 and promising to provide it free to any patient who needed it. The company said on Wednesday that it had applied to the Food and Drug Administration for emergency use authorization. Scientists noted that the trials of the antibody cocktail are far from complete, and that Mr. Trump is taking a variety of drugs that may have explained why he said he felt better. Dr. Anthony S. Fauci, the nation’s leading expert on infectious diseases, said that Mr. Trump might be right that the treatment he received has helped him in his fight with Covid-19 — but that his case alone doesn’t prove it. “I think it’s a reasonably good chance that the antibody that he received, the Regeneron antibody, made a significant difference in a positive way in his course,” Dr. Fauci, who is not involved in the president’s care, said on Thursday during an interview on MSNBC. But he pushed back against Mr. Trump’s claim that the treatment has now been shown to be a “cure” for the disease, which has killed more than 210,000 Americans so far. The White House did not immediately respond to a request for comment. In July, the International Society for Stem Cell Research sent a letter to the Human Fetal Tissue Research Ethics Advisory Board at the National Institutes of Health, urging the board to allow fetal tissue to be used to develop treatments for Covid-19 and for other diseases. “Fetal tissue has unique and valuable properties that often cannot be replaced by other cell types,” the letter said. In August, the board rejected 13 of the 14 proposals involving fetal tissue. The approved proposal relied on tissue that had already been acquired.